research

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma

Authors
    Publication date
    4 November 2015
    Publisher
    BioMed Central
    Doi

      Abstract

      Abstract is not available.

        Similar works

        Full text

        thumbnail-image

        Available Versions

        Springer - Publisher Connector

        redirect
        Last time updated on 30/04/2017